Navigation Links
Clinical Results for Oramed's Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
Date:5/1/2013

s and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-79
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
2. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
3. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
4. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
5. Elekta to Highlight Clinical and Safety Advantages of Gamma Knife Radiosurgery at 2013 AANS Meeting
6. Anterios, Inc., Announces Corporate Financing To Further Clinical Development Of Its Topical Botulinum Product
7. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
8. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
9. Statement from the Cystic Fibrosis Foundation on Promising Phase 2 Clinical Trial Results of Kalydeco and VX-661 (Vertex Pharmaceuticals Inc.)
10. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
11. Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014 Many new dentists who are opening ... ensure that their practice will be a success. DentalDisposables.net is ... they use the most can make all the difference. Dentistry ... recently discovered that purchasing discount dental supplies can ... According to successful dentists across the United States ...
(Date:7/24/2014)... 2014  Kinex Pharmaceuticals announced the receipt of an ... Ointment for the commencement of a Phase I clinical ... IND to be allowed by the US FDA in ... synthetic, orally active and highly selective inhibitor of Src ... induction of p53, G2/M arrest of proliferating cell populations ...
(Date:7/24/2014)... 24, 2014 Research and Markets  has ... Market by Product, Component, Application and Geography - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to witness a moderate growth as the markets of ... almost reached the saturation levels. The demand is expected ...
Breaking Medicine Technology:Dental Supplies Online is Key to Dental Success...Really! 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2
... College of Emergency Physicians 2009 Scientific Assembly ... medical device company developing innovative portable and ... launch of its new palm-sized, affordable ultrasound ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091005/SF86741-a ) , (Logo: ...
... 5 Bausch & Lomb, the global eye health ... of Tubilux Pharma S.p.A. , Tubilux is a privately ... range of proprietary, over-the-counter, and branded generic products primarily ... countries. , Under the terms of the agreement, Bausch ...
Cached Medicine Technology:Signostics Introduces the World's Smallest Ultrasound Product for Global Demands of Affordable Healthcare 2Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux 2
(Date:7/24/2014)... 24, 2014 Members of the Iowa State ... CCIM, Senior Associate of Sales at OutcomesMTM, as their Chairperson. ... to the Board and that his peers chose to keep ... provide the best I can for the citizens of Iowa,” ... positioned to provide a special insight to concerns and issues ...
(Date:7/24/2014)... new study has shown that it is possible to predict ... short-term effects of that same exposure. The findings, which currently ... it possible to develop simpler and cheaper tests to screen ... Despite an overall decrease in incidence of and mortality from ... the disease in their lifetime, and around 20 percent will ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... Human Papillomavirus Vaccination (HPV) even after becoming sexually ... results than those who were never vaccinated. These ... Diseases . , Researchers from Boston University ... conducted a cross-sectional study of 235 women age ... HPV status and demographic and behavioral characteristics were ...
(Date:7/24/2014)... July 24, 2014 According to ... Business Models, Technology Roadmap, Forecasts and Analysis - ... is expected to reach $7.7 billion by 2018 ... , Browse 102 market data tables and 30 ... on “3D Mapping Market: Global Advancements, Business Models, ...
Breaking Medicine News(10 mins):Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... , , Congressman Chaka Fattah (D-PA) ... America,s healthcare system. , , WASHINGTON, Aug. 17 ... If real reform is to take place it must include a public ... airport in any major city they deliberate how they will get to their ...
... , , CHESTERFIELD, ... RELV ), a nutrition and direct selling company, today launched ... company,s line of proprietary nutritional supplements. , , ... Reliv,s breakthrough r(TM) skincare collection that combines some of the ...
... , , SAN FRANCISCO, ... leader in healthcare data management and decision support solutions ... a strategic alliance with CACTUS Software, a leading provider ... expand the capabilities and simplify the ability of healthcare ...
... , CHICAGO, Aug. 17 Presidential ... furnished two bedroom apartment to the University of Illinois Medical Center ... undergoing care at the medical center. , , ... Towers felt that this was a great way to give back ...
... PARK, N.J., Aug. 17 Managed Health Care Associates, Inc. ... joined MHA as Vice President & General Counsel. In ... all legal matters for the company, including healthcare compliance, contract ... and CFO of MHA commented "The establishment of this important ...
... Volumizing the Brow ... ... eyes change in generally predictable ways: the skin thins and becomes less elastic, brows may ... more prominent. While surgery has long been the accepted standard and offers significant benefits ...
Cached Medicine News:Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 2Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 3Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 2Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 3Health News:Presidential Towers Donates Apartment to the University of Illinois Medical Center 2Health News:MHA Announces Gloria Barr, Esq. as Vice President & General Counsel 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 3
... ESR-10 Manual Rack is a manual ... the erythrocyte sedimentation rate (ESR) of ... 1.2ml Streck ESR-Vacuum Tubes. The rack ... simultaneously. The ESR-10 Manual Rack exhibits ...
... assayed control for immunophenotyping with Beckman Coulter® ... the accuracy and reproducibility of all the ... including red blood cell lysis. Reference values ... lymphocytes, B lymphocytes, granulocytes, monocytes, and NK ...
... storage and transport solution formulated ... cells in samples without reducing ... Samples treated with Cyto-Chex can ... seven days prior to analysis ...
... specially designed for use with Coulter® ... package includes diluent, lysing agent, cleaning ... The 15L package configuration includes diluent, ... card. The shelf life is one ...
Medicine Products: